Imugene Ltd has released a press release.
Imugene Granted India Patent for Oncolytic Virotherapy CF33
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Imugene OnCARlytics Patent Allowance in China
- Azer-cel demonstrates two additional Complete Responses
- Imugene Receives A$20 million for Convertible Notes Issuance
- Imugene Receives $11.7m R&D Tax Refund
- First Australian Patient Dosed in Phase 1b azer-cel Trial
Later from Imugene
- S&P DJI Announces March 2025 Quarterly Rebalance
- Azer-cel Granted FDA Fast Track Designation in Blood Cancer
- Notice of Extraordinary General Meeting/Proxy Form
- Two Additional Complete Responses in azer-cel Ph1b trial
- Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene